Health Control Beliefs and Attitude Toward Treatment in Psychiatric and Non-Psychiatric Clinical Samples

Laszlo Pogany1,2 and Judit Lazary1,2*

1 National Institute of Mental Health, Neurology and Neurosurgery, Budapest, Hungary, 2 Janos Szentagothai Doctoral School of Neuroscience, Budapest, Hungary

Although there is accumulating evidence on the potential influencing factors of medication adherence, the knowledge about patients’ attitudes and beliefs toward treatment is only partly utilized in adherence-improving strategies. Several internal and external factors determining adherence have been described regarding many chronic somatic diseases but in recent research, insight on psychiatric patients has been exclusively lacking. As a result, there is a scarcity of effective adherence-improving interventions. Identification of any specific differences or similarities between the attitudes toward treatment of psychiatric and non-psychiatric patients would help to support adherent behavior.

We recruited 189 participants from four departments of general psychiatry (GEN PSYCH, n = 106), addictology (ADDICT, n = 42) and somatic diseases (NON PSYCH, n = 41). The Patient’s Health Belief Questionnaire on Psychiatric Treatment (PHBQPT) was performed to assess the patients’ attitude toward drug treatment, perceived health locus of control, and psychological reactance.

The most robust difference of the PHBQT scores occurred between the GEN PSYCH and ADDICT subgroups. ADDICT patients scored significantly higher on the internal and external health locus of control and on the Psychological Reactance subscale as well. While GEN PSYCH subjects provided higher scores on the Positive Aspect of Medication compared to ADDICT persons. Interestingly, the only difference between the GEN PSYCH and NON-PSYCH groups was the more pronounced mistrust in physicians in the case of psychiatric patients.

Our data suggest that mistrust toward medication does not differ in psychiatric and non-psychiatric samples, while the acceptance of the doctor’s competency may be stronger in the non-psychiatric sample. The analysis of these factors provides information which could help us better understand this important issue and to develop more efficient interventions for improving adherence.

Keywords: compliance, adherence, drug attitude, health belief, psychiatric treatment
INTRODUCTION

Medication non-adherence is one of the most challenging problems of healthcare. In the case of patients requiring psychiatric treatment, non-adherence is considered to be one of the major factors which influence the course of illness and the outcome. According to a report from the WHO, about 50% of patients with a chronic disease are non-adherent to their medication (1) and some authors suggest that improving adherence at a population level may have a higher influence on health than the discovery of a new compound (2). Detailed reviews are available about the factors influencing adherence (3–8) and there are some interesting data on the mediating role of depression on adherence in chronic somatic diseases, such as hypertension (9), cardiovascular disease (2), diabetes (10), and chronic kidney disease (11). However, few direct comparisons have been made between somatic and psychiatric patients’ adherence. Further evidence suggested that health-related locus of control can moderate the relationship between a serious somatic disease causing disability and the consecutive occurring depressive symptoms. Authors emphasized the importance of assessment of control beliefs of patients undergoing treatment for serious somatic illness in order to facilitate the recovery process (12).

Medication taking is a complex behavior and several potentially influencing factors have been investigated and proven to correlate with it. The results have shown that demographic, medical, or personality factors have less influence on adherence than psychological and emotional aspects. Comprehensive analysis of these factors led to the recognition of the importance of beliefs about medication’s impact on health (13). Further studies confirmed the crucial role of social cognition in medication adherence and Social Cognition Models appeared in the literature of medication adherence (14). One of these concepts is the Health Locus of Control (HLOC) which has been identified as a determining dimension of medication adherence in several fields of medicine (4, 15). The Multidimensional Health Locus of Control Scale was developed by Wallston, Wallston, and de Vellis in order to measure HLOC. HLOC refers to “the degree to which individuals believe that their health is controlled by internal vs. external factors” Wallston et al. (25). The external factor has been divided into two subfactors, such as “chance or fate” and “powerful others.” Drug attitude and health control belief have been intensively studied in numerous fields of medicine in order to understand its complexity and impact on adherence. Self-efficacy also plays a positive role in developing patients’ attitudes toward treatment. Patients with higher beliefs in their capabilities (higher self-efficacy) are more likely to be pharmacophilic (16).

Medication adherence can be negatively influenced by side effects, stigma, fear of addiction, previous negative experiences, negative attitudes toward drug treatment, and poor insight (17–19). In an exploratory study of adherence of schizophrenic patients it was found that the patients believing that their illness can be controlled by themselves and/or by their physicians were more likely to follow their prescriptions. The link between health locus of control and adherence appeared to be refined by insight (20). According to the results of one study, psychiatric patients’ attitudes toward medication could be negatively influenced by educational level, patients with a higher educational level have been shown to be more skeptical about the usefulness of psychoactive drugs (16).

In this pilot study we investigated the role of beliefs and health locus of control in influencing the attitude toward pharmacological treatment in samples of patients with general psychiatric, addictive, and somatic disorders.

METHODS

Study Sample

A total of 195 participants were recruited from four different departments of general psychiatry (Departments A, B, C, and D; hereinafter together referred to as GEN PSYCH, n = 112), a department of addictology (ADDICT, n = 42), a department of internal medicine (IM, n = 20), and a department of neurology (NEUR, n = 21) of the Nyíro Gyula National Institute of Psychiatry and Addictions, Budapest, Hungary. A dataset of 189 subjects were entered into the final statistical analysis, as six patients were excluded because of missing data (106 from GEN PSYCH, n = 42 from ADDICT, n = 41 subjects from IM+NEUR depts). Subjects were asked to participate in the survey anonymously. Patients treated at the department of addictology were admitted to the department after a motivational interview. Participants from the GEN PSYCH were diagnosed with psychiatric disorders coded ICD F2, F3, and F4. All patients were voluntarily treated. Patients being treated with at least one psychotropic medication (generally an anxiolytic) from IM and NEUR were selected to participate in the study. For the comparative analysis of different clinical samples with altered adherence characteristics, three subgroups were created: patients from the departments of general psychiatry (GEN PSYCH); department of addictology (ADDICT); and patients from the departments of internal medicine and neurology (NON-PSYCH). The study was approved by the Hungarian Central Ethical Committee, Budapest, Hungary (number of approval: 45735-5/2020). A signed informed consent was obtained from all subjects. The study was conducted according to the Declaration of Helsinki.

Questionnaires

We used the Hungarian version of the Patient’s Health Belief Questionnaire on Psychiatric Treatment (PHBQPT) to assess the patients’ attitude toward drug treatment, perceived health locus of control, and psychological reactance developed by Armitage and Conner (14), De las Cuevas et al. (21), Pogany et al. (22). The questionnaire consists of 17 items from three previously validated scales, the Drug Attitude Inventory (DAI-10) (23), the Hong Psychological Reactance Scale (HPRS) (24), and the Multidimensional Health Locus of Control (MHLC, Form C) (25) on five subscales (Positive Aspects of Medications, Negative Aspects of Medications, Doctor-HLOC, Internal-HLOC, and Psychological Reactance). Patients can rate on a 6-point Likert scale the degree to which they agreed or disagreed with the statements, from strongly disagree to strongly agree. The
Hungarian version of the PHBQPT questionnaire was validated by our research group. Originally, this newly developed questionnaire was validated in a sample of psychiatric patients. In the present study we decided to use this instrument also in the case of patients treated at internal medicine and neurology departments who were taking at least one psychotropic agent. The patients involved in the study were hospitalized at one of the four departments of the general psychiatry, were treated for addictions, or underwent treatment at the internal medicine and neurology department. The involvement of these different subpopulations aimed to compare the potential effects of the awareness of being treated for a psychiatric illness on the beliefs and attitude toward medication treatment.

Data Analysis
To test the distribution of the scores we used the Kolmogorov-Smirnov test. To assess the differences between clinical subgroups (GEN PSYCH vs. ADDICT and GEN PSYCH vs. NON-PSYCH), the mean scores of items and subscales of the PHBQPT were compared using one-way ANOVA or t-test in the case of normal distribution. For comparing the mean scores between two groups we used the Mann-Whitney U test. The ANOVA test and post hoc Tukey’s test was performed to analyse the differences among the mean scores of the three groups. Chi-square tests were performed in the case of binary categorical variables. The effects of age and gender on the dependent variables were calculated by a general linear model. Missing data were excluded from the statistical analyses. Results were accepted as significant if the α-level was <0.05. All statistic tests were run in the SPSS 24.0 program.

RESULTS
Descriptive Statistics
The distribution of mean scores deviated significantly from normal in the case of all subscales of PHBQPT according to the Kolmogorov-Smirnov test (p > 0.001 in all cases). The mean age of the NON-PSYCH subsample was significantly higher than the mean age of the GEN PSYCH or ADDICT subpopulations (p < 0.05). Gender ratio was equilibrated in the PSYCH subsample, but women were overrepresented in the NON-PSYCH sample (p = 0.012). The scores on the PHBQPT items and subscales showed similar trends with the results of De las Cuevas et al. (21). The effect of age and gender were tested by general linear models on the PHBQPT subscales. We found that in the NON-PSYCH sample only Psychological Reactance depended on the gender (p = 0.045). However, age had a significant effect on the Doctor-HLOC subscale in both PSYCH subsamples (p = 0.025; p = 0.023; respectively). Interestingly, Internal-HLOC was gender-dependent only in the ADDICT subgroup (p = 0.026). The detailed results of descriptive statistical analyses are shown in Tables 1, 2.

Regarding the associations of mean scores of the PHBQPT subscales among the three clinical samples, we found significant associations in the case of Positive Aspect (pANOVA = 0.004), Doctor HLOC (pANOVA = 0.002); Internal HLOC (pANOVA = 8x10^-7), and Psychological Reactance (pANOVA = 0.43) (Figure 1). Results of the post hoc paired-samples tests are described in sections Comparison of the PHBQPT scores in the GEN PSYCH and ADDICT clinical subsamples and Comparison of the PHBQPT scores in the GEN PSYCH and NON-PSYCH clinical subsamples.

Comparison of the PHBQPT Scores in the GEN PSYCH and ADDICT Clinical Subsamples
Regarding pronounced differences in the attitude toward medication in patients with addictions, first we compared the PHBQPT scores between GEN PSYCH and ADDICT subgroups. As it was expected, participants treated for an addiction gave significantly different responses on almost all items of the questionnaire. Patients with addictions scored significantly higher on items 1, 2, 3, 6, 7, 8, 12, and 14 (all p-values < 0.05). In contrast, robustly higher scores were given by GEN PSYCH subgroup members on items 4, 11, 15, and 16 (all p-values < 0.05). Significantly higher scores on the Positive Aspects of the Medications subscale were found in the GEN PSYCH subgroup population while there was no difference in Negative Aspect between the two subgroups. However, patients with addictions scored significantly higher on the Doctor-HLOC, Internal-HLOC, and Psychological Reactance subscales (all p-values < 0.05). Results of the comparative analyses between GEN PSYCH and ADDICT subsamples are presented in Table 3 and Figure 1.

Comparison of the PHBQPT Scores in the GEN PSYCH and NON-PSYCH Clinical Subsamples
Considering the major differences between the GEN PSYCH and ADDICT subgroups, we performed comparison analysis of the PHBQPT scale in the NON-PSYCH sample only vs. the GEN PSYCH subgroup. In this analysis the highest degree of agreement was found for the item “Whenever my condition worsens, I should consult a medically trained professional” in both subsamples (5.3 ± 1.1 and 5.6 ± 0.7; p > 0.05), similar to the results of the study of De las Cuevas et al. (21). However, psychiatric patients considered it significantly less important to follow their physician’s suggestions (5.1 ± 1.0 vs. 5.5 ± 0.8; p = 0.03) and found regular visits to their doctors to be less effective (4.6 ± 1.4 vs. 5.2 ± 1.1; p = 0.010). Surprisingly, resistance...
against others’ influence was more pronounced among patients with somatic disorders than in the PSYCH subgroup (4.3 ± 1.4 vs. 5.0 ± 1.6; $p = 0.01$). Concerning the PHBQPT subscales, NON-PSYCH participants scored significantly higher on the Doctor-HLOC subscale compared to the GEN PSYCH group (15.3 ± 2.7 vs. 15.9 ± 2.7; $p = 0.04$). The results of comparative analysis between the GEN PSYCH and NON-PSYCH samples are presented in Table 4 and Figure 1.

**DISCUSSION**

This is the first report on a comparative analysis of the drug attitude and health concept of different clinical samples. Despite the fact that drug adherence is a hot topic in clinical psychopharmacology and it is generally considered that psychiatric patients are less adherent with their treatment and the mistrust toward medication is more common among them compared to the non-psychiatric patient population, there have not been any direct comparisons regarding these aspects in psychiatric and non-psychiatric subsamples so far. The analysis of different samples may provide valuable information which could help us better understand the specific features and the general common mechanisms behind the attitudes toward treatment of patients suffering from different chronic diseases. This information can be used to develop more efficient interventions for improving adherence.

Poor treatment adherence leads to an enormous healthcare and economical burden. According to Krueger et al. (26), self-reported data overestimate medication adherence in clinical practice by as much as 200%. Lapane et al. (27) demonstrated that while doctors estimated that 9% of patients do not talk about their non-adherence, in reality 83% of patients reported that they would never tell their physician if they did not plan on picking up a prescription. According to some financial analyses, non-adherence leads to a loss of 100–300 billion dollars in the United States annually (IMS Institute for Healthcare Informatics). Certain estimations suggest that improving adherence to diabetes medication would prevent 699,000 emergency department visits and 341,000 hospitalizations each year in the United States of America (28). Some statistical data suggest that 33–69% of the hospitalizations are related to poor adherence (29).

The results of our study have shown that there is a more robust difference regarding attitude toward medication between ADDICT patients and GEN PSYCH patients than between the latter population and NON PSYCH subjects. Although positive aspects of medication appeared more pronounced in the GEN PSYCH sample, the trust in doctors and feelings of personal responsibility for their own health were presented at a higher
level among patients with addictions. Participants belonging to the GEN PSYCH sample were more skeptical regarding the importance of seeing their physician than patients treated due to somatic diseases, as it is shown by the reduced Doctor-HLOC subscale score. GEN PSYCH patients do not believe that regularly seeing their doctor would decrease the risk of getting worse and they do not think that “following the doctor’s order to the letter” is the best way to keep their condition from getting any worse. Analyzed together with other items of the scale, it can be concluded that GEN PSYCH patients believe that they might need some help, but they frequently refuse to follow the instructions of the medical professionals. However, according to the Positive and Negative Aspect subscale scores, beliefs and attitude toward medication do not differ significantly in the GEN PSYCH and NON-PSYCH samples.

In conclusion, the attitude toward medication was more positive in the GEN PSYCH than in the ADDICT subsamples, and similar in the GEN PSYCH and NON-PSYCH samples. Concerning the health control locus, the strongest external and internal health control belief appeared in the ADDICT subgroup while only the Doctor HLOC was higher in the NON-PSYCH than in the GEN PSYCH sample. Nevertheless, attitude toward medication is partially associated with beliefs and health locus of control.

Despite the fact that in the NON-PSYCH sample there were higher levels of external locus of control than in the psychiatric group, it seems that the level of mistrust toward medication is similar in both samples. These results are in concordance with the conclusions of a review published by Brown et al. (5). They emphasized that besides individual experiences the increasing mistrust of societies toward healthcare systems contribute to the negative beliefs. The authors highlighted that patients’ negative beliefs are often stronger than their clinicians would suppose. An important factor contributing to patients’ mistrust is the assumed relationship between the pharmaceutical companies and doctors. Grande et al. reported that 55% of patients believed that their doctors received gifts from the companies and this belief was associated with lower trust in their physician and doubled the chance of mistrust in the entire healthcare system (30). Another factor leading to mistrust was the contradiction between the information acquired from different sources (healthcare provider, media, internet) (5). De las Cuevas et al. (31) found

### TABLE 3 | Comparison of PHBQPT item scores and subscales between ADDICT vs. GEN PSYCH subsamples.

| Item |
|---|
| GEN PSYCH | ADDICT | p-value |
| I am directly responsible for my condition getting better or worse | 4.8 ± 1.3 | 5.6 ± 0.8 | 0.001 |
| If I see my doctor regularly, I am less likely to have a problem with my condition | 4.6 ± 1.4 | 5.2 ± 1.3 | 0.007 |
| When someone forces me to do something, I feel like doing the opposite | 2.9 ± 1.4 | 3.7 ± 1.4 | 0.004 |
| For me, the good things about medication outweigh the bad | 4.3 ± 1.3 | 3.4 ± 1.8 | 0.001 |
| I feel strange, “doped up”, on medication | 3.7 ± 1.3 | 3.5 ± 1.8 | NS |
| The main thing which affects my condition is what I myself do | 4.3 ± 1.3 | 5.3 ± 0.8 | 0.000 |
| Following doctor’s orders to the letter is the best way to keep my condition from getting any worse | 5.1 ± 1.1 | 5.6 ± 0.5 | 0.003 |
| I resist the attempts of others to influence me | 4.3 ± 1.4 | 4.8 ± 1.4 | 0.041 |
| Medications make me feel more relaxed | 4.2 ± 1.3 | 3.8 ± 1.7 | NS |
| Medications make me feel tired and sluggish | 3.6 ± 1.7 | 3.6 ± 1.6 | NS |
| I feel more normal on medication | 4.2 ± 1.4 | 3.5 ± 1.7 | 0.011 |
| If my condition takes a turn for the worse, it is because I have not been taking proper care of myself | 3.9 ± 1.5 | 4.9 ± 1.2 | 0.000 |
| Whenever my condition worsens, I should consult a medically trained professional | 5.3 ± 1.1 | 5.6 ± 0.7 | NS |
| It is unnatural for my mind and body to be controlled by medication | 3.4 ± 1.6 | 4.1 ± 1.9 | 0.012 |
| My thoughts are clearer on medication | 3.6 ± 1.6 | 2.7 ± 1.7 | 0.002 |
| Taking medication will prevent me from having a breakdown | 4.0 ± 1.4 | 3.3 ± 1.7 | 0.015 |
| I become angry when my freedom of choice is restricted | 4.2 ± 1.3 | 4.0 ± 1.6 | NS |

**Subscales**

**Attitudes toward medication**

| Positive Aspects of Medication | 20.3 ± 5.4 | 16.8 ± 7.3 | 0.001 |
| Negative Aspects of Medication | 10.5 ± 2.9 | 10.9 ± 3.8 | NS |

**Perception of health controls**

| Doctor-HLOC | 14.8 ± 2.9 | 16.4 ± 1.5 | 0.001 |
| Internal-HLOC | 12.9 ± 3.3 | 15.8 ± 1.9 | 0.000 |
| Psychological Reactance | 11.3 ± 2.7 | 12.5 ± 2.8 | 0.012 |

Mean scores were compared with Mann-Whitney U tests.

PHBQPT, Patient’s Health Belief Questionnaire on Psychiatric Treatment.
that highly psychological reactant patients were more likely to be noncompliant; they generally resist any guidance or assistance. Mago et al. (32) reported that in a sample of 2,096 subjects suffering from major depressive disorder, the most frequent negative emotion reported by patients regarding their medication was frustration (29.8% of respondents). Concerning feelings about their healthcare providers, the majority reported feeling understood, trust, and confidence but almost 20% reported frustration due to not feeling heard, ineffective treatment, and feeling rushed/lack of quality visit. The reasons for frustration with medication were lack of effectivity and tolerability issues. In contrast, physicians estimated that only 11% of patients were frustrated with their medications and 5% with the healthcare quality (32). In another survey, data of 3,684 subjects were analyzed concerning compliance to antidepressant treatment. They found that 22% was the overall level of compliance, thus only one in four patients complied with treatment. Surprisingly, better compliance was observed in patients with polypharmacy (33).

Understanding patients’ health beliefs and attitudes toward drug treatment is needed for successful therapy. It is also essential that patients who are in their first contact with mental health care professionals are given comprehensive and appropriate information regarding the planned treatment (34).

Nevertheless, there are some limitations in this study, as, in the case of the patients recruited from the somatic departments, the sample size was smaller since the mean age of patients treated at the internal medicine and neurological departments was higher and their general health status was worse. The occurrence of neurocognitive disorders was higher in this group compared to the group of patients treated at departments of general psychiatry. Thus, we found fewer patients who were eligible for enrollment into the study. Another limitation is that we did not investigate treatment adherence (all patients were hospitalized throughout the entire duration of the study). On the other hand, it is the strength of our study that we are among the first researchers to have used
the recently developed PHBQPT questionnaire in different clinical samples.

In conclusion, mistrust toward medication did not differ in the GEN PSYCH and NON-PSYCH samples, while acceptance of the doctor's competency was stronger in the non-psychiatric subsample. In other words, our findings suggest that psychiatrists have to deal with more intense mistrust which can be partly explained by the assessed population (psychiatric patients hospitalized mainly due to acute decompensation) and this does not correlate with the level of patients' confidence in medication.

Many aspects still need to be elucidated regarding the attitudes of the patients toward medication and healthcare professionals. Clinicians generally tend to overestimate the level of adherence to treatment of patients. More attention needs to be paid to the changeable variables in the background of beliefs and attitudes toward treatment in order to implement efficient adherence-improving interventions. Our results indicate that mental health professionals would need reliable methods for the systematic assessment and modification of patients' attitude toward treatment.

REFERENCES

1. De Geest S, Sabate E. Adherence to long-term therapies: evidence for action. Eur J Cardiovasc Nurs. (2003) 2:323. doi: 10.1016/S1474-5151(03)00091-4
2. Bane, C, Hughes CM, and McElney JC. The impact of depressive symptoms and psychosocial factors on medication adherence in cardiovascular disease. Patient Educ Couns. (2006) 60:187–93. doi: 10.1016/j.pec.2005.01.003
3. Conn VS, Rupp TM. Medication adherence outcomes of 771 intervention trials: systematic review and meta-analysis. Prev Med. (2017) 99:269–76. doi: 10.1016/j.ympmed.2017.03.008
4. Cheng C, Cheung MW, Lo BC. Relationship of health locus of control with specific health behaviours and global health appraisal: a meta-analysis and effects of moderators. Health Psychol Rev. (2016) 10:660–77. doi: 10.1080/17437199.2016.1219672
5. Brown MT, Bussell J, Dutta S, Davis K, Strong S, Mathew S. Medication adherence: truth and consequences. Am J Med Sci. (2016) 351:387–99. doi: 10.1016/j.amjms.2016.01.010
6. Nafradi I, Nakamoto K, Schulz PJ. Is patient empowerment the key to promote adherence? A systematic review of the relationship between self-efficacy, health locus of control and medication adherence. PLoS ONE. (2017) 12:e0186458. doi: 10.1371/journal.pone.0186458
7. Kelly M, McCarthy S, Sahm LJ. Knowledge, attitudes and beliefs of patients and carers regarding medication adherence: a review of qualitative literature. Eur J Clin Pharmacol. (2014) 70:1423–31. doi: 10.1007/s00228-014-1761-3
8. West LM, Borg Theuma R, Cordina M. Health locus of control: Its relationship with medication adherence and medication wastage. Res Social Adm Pharm. (2018) 14:1015–9. doi: 10.1016/j.sapharm.2017.12.003
9. Maguire LK, Hughes CM, McElney JC. Exploring the impact of depressive symptoms and medication beliefs on medication adherence in hypertension—a primary care study. Patient Educ Couns. (2008) 73:371–6. doi: 10.1016/j.pec.2008.06.016
10. Chao J, Nau DP, Aikens JE, Taylor SD. The mediating role of health beliefs in the relationship between depressive symptoms and medication adherence in persons with diabetes. Res Social Adm Pharm. (2005) 1:508–25. doi: 10.1016/j.sapharm.2005.09.002
11. Cvegrows JA, Christensen AJ, Lawton WJ. Health locus of control and depression in chronic kidney disease: a dynamic perspective. J Health Psychol. (2005) 10:677–86. doi: 10.1177/13591053050555320
12. Zirk M, Storm V. Subjective stroke impact and depressive symptoms: indications for a moderating role of health-related locus of control. Front Psychiatry. (2019) 10:918. doi: 10.3389/fpsyt.2019.00918
13. Horne R, Weinman J. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res. (1999) 47:555–67. doi: 10.1016/S0022-3999(99)00057-4
14. Armitage CJ, Conner M. Social cognition models and health behaviour: a structured review. Psychol Health. (2000) 15:173–89. doi: 10.1080/0887044000840299
15. Williams DM, Rhodes RE. The confounded self-efficacy construct: conceptual analysis and recommendations for future research. Health Psychol Rev. (2016) 10:113–28. doi: 10.1080/17437199.2014.941998
16. De Las Cuevas C, Penate W. Explaining pharmacophobia and pharmacophilia in psychiatric patients: relationship with treatment adherence. Hum Psychopharmacol. (2015) 30:377–83. doi: 10.1002/hup.2487
17. Ayalon L, Arean PA, Alvidrez J. Adherence to antidepressant medications in black and Latino elderly patients. Am J Geriatr Psychiatry. (2005) 13:572–80. doi: 10.1097/00019442-200507000-00005
18. Cooper C, Carpenter I, Katona C, Schroll M, Wagner C, Fialova D, et al. The AdHOC study of older adults' adherence to medication in 11 countries. Am J Geriatr Psychiatry. (2005) 13:1067–76. doi: 10.1097/00019442-200512000-00006
19. Givens JL, Datto CJ, Ruckdeschel K, Knott K, Zubritsky C, Oslin DW, et al. Older patients' aversion to antidepressants: A qualitative study. J Gen Intern Med. (2006) 21:146–51. doi: 10.1111/j.1525-1497.2005.00296.x
20. Combes C, Feral F. [Drug compliance and health locus of control in schizophrenia]. Encephale. (2011) 37(Suppl. 1):S11–8. doi: 10.1016/j.encep.2010.08.007
21. De Las Cuevas C, de Leon J. Development and validation of the Patient's Health Belief Questionnaire on Psychiatric Treatment. Patient Prefer Adherence. (2019) 13:527–36. doi: 10.2147/PPA.S201144
22. Pogany L, De las Cuevas C, Lazary J. The validation and analysis of the Patient's Health Belief Questionnaire on Psychiatric treatment in a sample of Hungarian psychiatric patients. Neuropsychopharmacologia Hungarica. (2021) 23:221–31.
23. Hogan TP, Awad AG. Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures. Psychol Med. (1992) 22:347–52. doi: 10.1017/S0033291700030282

DATA AVAILABILITY STATEMENT

The datasets generated for this study will not be made publicly available. There is no such an option by the ethical permission.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Hungarian Central Ethics Committee. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

LP recruited the patients, collected data, and prepared the manuscript. JL contributed to the study design, statistical analysis, and review of the manuscript.

FUNDING

This study was supported by the National Research, Development and Innovation Office’s FK 131315 research grant.
24. Hong SM. Hong’s psychological reactance scale: a further factor analytic validation. Psychol. Rep. (1992) 70:512–4. doi: 10.2466/pr0.1992.70.2.512
25. Wallston KA, Wallston BS, DeVellis R. Development of the multidimensional health locus of control (MHLC) scales. Health Educ Monogr. (1978) 6:160–70. doi: 10.1177/109019817800600107
26. Krueger KP, Berger BA, Felkey B. Medication adherence and persistence: a comprehensive review. Adv Ther. (2005) 22:313–56. doi: 10.1007/BF02850081
27. Lapane KL, Dubé CE, Schneider KL, Quilliam BJ. Misperceptions of patients vs providers regarding medication-related communication issues. Am J Manag Care. (2007) 13:613–8.
28. Jha, AK, Aubert RE, Yao J, Russell Teagarden J, Epstein RS. Greater adherence to diabetes drugs is linked to less hospital use and could save nearly $5 billion annually. Health Aff (Millwood). (2012) 31:1836–46. doi: 10.1377/hlthaff.2011.1198
29. Osterberg, L, Blaschke T. Adherence to medication. N Engl J Med. (2005) 353:487–97. doi: 10.1056/NEJMra050100
30. Grande D, Shea JA, Armstrong K. Pharmaceutical industry gifts to physicians: patient beliefs and trust in physicians and the health care system. J Gen Intern Med. (2012) 27:274–9. doi: 10.1007/s11606-011-1760-3
31. De Las Cuevas C, Penate W, Sanz EJ. The relationship of psychological reactance, health locus of control and sense of self-efficacy with adherence to treatment in psychiatric outpatients with depression. BMC Psychiatry. (2014) 14:324. doi: 10.1186/s12888-014-0324-6
32. Mago R, Fagiolini A, Weiller E, Weiss C. Understanding the emotions of patients with inadequate response to antidepressant treatments: results of an international online survey in patients with major depressive disorder. BMC Psychiatry. (2018) 18:33. doi: 10.1186/s12888-018-1625-3
33. Serna MC, Real J, Cruz I, Galván L, Martin E. Monitoring patients on chronic treatment with antidepressants between 2003 and 2011: analysis of factors associated with compliance. BMC Public Health. (2015) 15:1184. doi: 10.1186/s12889-015-2493-8
34. De Las Cuevas C, Sanz EJ. Attitudes toward psychiatric drug treatment: the experience of being treated. Eur J Clin Pharmacol. (2007) 63:1063–7. doi: 10.1007/s00228-007-0358-5

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Pogany and Lazary. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.